Product Pathways
Products
BCP0030 BIBW2992
BIBW-2992 is a potent oral, irreversible combined EGFR/HER2 inhibitor.
BCP0031 BMS-599626(HCl)
BMS-599626,an orally bioavailable pan-HER tyrosine kinase inhibitor with potential antineoplastic activity. BMS-599626 inhibits human epidermal growth factor receptors (HER) HER1, HER2 and HER4, thereby inhibiting the proliferation of tumor cells that overexpress these receptors.
BCP0066 Lapatinib Ditosylate
Lapatinib is a potent inhibitor of EGFR kinase (Ki = 3 nM), ErbB-2 kinase (Ki = 13 nM), ErbB-4 kinase (Ki = 347 nM).
BCP0208 CP-724714
CP-724,714 is a potent, selective inhibitor of HER2/ErbB2 with IC50 of 10 nM and also inhibits EGFR with IC50 of 6.4 μM.
BCP0148 Neratinib(HKI272)
Neratinib is an orally available, irreversible tyrosine kinase inhibitor with IC50 of 59 nM and 92 nM for HER2 and EGFR, respectively.
BCP0151 Lapatinib
Lapatinib is a potent inhibitor of EGFR kinase (Ki = 3 nM), ErbB-2 kinase (Ki = 13 nM), ErbB-4 kinase (Ki = 347 nM).
BCP0177 Canertinib dihydrochloride(CI 1033)
CI-1033 effectively inhibits the growth of esophageal squamous cell carcinoma which co-expresses both EGFR and HER2 with the inhibition of phosphorylation of both MAPK and AKT.
BCP0342 AEE788
AEE788 is a novel dual inhibitor of EGFR/ErbB2 and VEGFR tyrosine kinases.
BCP0535 Canertinib(CI-1033)
CI-1033 effectively inhibits the growth of esophageal squamous cell carcinoma which co-expresses both EGFR and HER2 with the inhibition of phosphorylation of both MAPK and AKT.
BCP001122 ARRY380
ARRY-380 is an orally bioavailable, potent, selective, small-molecule tyrosine kinase inhibitor of HER2
第一页 1 2 最后页 
 
Only for research purpose , not for human consumption Copyright©2012 ShangHai Biochempartner Co.,Ltd.